Literature DB >> 7929774

Tentative evidence of AIDS-associated biotype of Mycobacterium kansasii.

E Tortoli1, M T Simonetti, C Lacchini, V Penati, P Urbano.   

Abstract

Previous studies revealed heterogeneous behavior within the species Mycobacterium kansasii against commercially available DNA probes (Accuprobe M. kansasii culture identification test; Gen-Probe); several isolates, conventionally identified as M. kansasii, failed in fact to hybridize. Looking for a possible association with phenotypic features, we tested a fully characterized panel of 69 clinical isolates of M. kansasii (19 of which were Accuprobe negative) with a semiquantitative micromethod which tests for 19 enzymatic activities (Api Zym; BioMérieux). The strains were from 25 hospitals in 18 Italian towns; 20 isolates came from human immunodeficiency virus type 1-positive patients who fulfilled the Centers for Disease Control criteria for AIDS diagnosis. On the basis of the whole set of phenotypic traits, our strains clustered in two groups, allowing the differentiation of biotypes within the species. There was a perfect association between biotype 2 and hybridization failures with Accuprobe and a very significant association between this novel biotype 2 and AIDS status, which suggests that it differs in virulence.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7929774      PMCID: PMC263792          DOI: 10.1128/jcm.32.7.1779-1782.1994

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  7 in total

1.  Two varieties of Mycobacterium kansasii with different clinical significance.

Authors:  L G WAYNE
Journal:  Am Rev Respir Dis       Date:  1962-11

2.  Niacin-positive Mycobacterium kansasii isolated from immunocompromised patients.

Authors:  I Nachamkin; R R MacGregor; J L Staneck; A Y Tsang; J C Denner; M Willner; S Barbagallo
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

3.  Evaluation of a commercial DNA probe assay for the identification of Mycobacterium kansasii.

Authors:  E Tortoli; M T Simonetti; C Lacchini; V Penati; C Piersimoni; V Morbiducci
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-03       Impact factor: 3.267

4.  The spectrum of Mycobacterium kansasii disease associated with HIV-1 infected patients.

Authors:  G T Valainis; L M Cardona; D L Greer
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

5.  Identification of an insertion sequence-like element in a subspecies of Mycobacterium kansasii.

Authors:  M Yang; B C Ross; B Dwyer
Journal:  J Clin Microbiol       Date:  1993-08       Impact factor: 5.948

6.  Evaluation of nonradioactive DNA probes for identification of mycobacteria.

Authors:  L Lebrun; F Espinasse; J D Poveda; V Vincent-Levy-Frebault
Journal:  J Clin Microbiol       Date:  1992-09       Impact factor: 5.948

7.  Identification of a genetically distinct subspecies of Mycobacterium kansasii.

Authors:  B C Ross; K Jackson; M Yang; A Sievers; B Dwyer
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

  7 in total
  13 in total

1.  Identification of 54 mycobacterial species by PCR-restriction fragment length polymorphism analysis of the hsp65 gene.

Authors:  F Brunello; M Ligozzi; E Cristelli; S Bonora; E Tortoli; R Fontana
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

2.  Rapid identification of mycobacteria to species level by PCR-restriction fragment length polymorphism analysis of the hsp65 gene and proposition of an algorithm to differentiate 34 mycobacterial species.

Authors:  A Devallois; K S Goh; N Rastogi
Journal:  J Clin Microbiol       Date:  1997-11       Impact factor: 5.948

3.  Intra- and interpatient variability of the hsp65 and 16S-23S intergenic gene region in Mycobacterium abscessus strains from patients with cystic fibrosis.

Authors:  Brigitte König; Ina Tammer; Veronika Sollich; Wolfgang König
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

4.  Clinical implications of Mycobacterium kansasii species heterogeneity: Swiss National Survey.

Authors:  Caroline Taillard; Gilbert Greub; Rainer Weber; Gaby E Pfyffer; Thomas Bodmer; Stefan Zimmerli; Reno Frei; Stefano Bassetti; Peter Rohner; Jean-Claude Piffaretti; Enos Bernasconi; Jacques Bille; Amalio Telenti; Guy Prod'hom
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

5.  Genotypic characterization of five subspecies of Mycobacterium kansasii.

Authors:  M Picardeau; G Prod'Hom; L Raskine; M P LePennec; V Vincent
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

6.  Evaluation of reformulated chemiluminescent DNA probe (AccuProbe) for culture identification of Mycobacterium kansasii.

Authors:  E Tortoli; M T Simonetti; F Lavinia
Journal:  J Clin Microbiol       Date:  1996-11       Impact factor: 5.948

7.  Utility of high-performance liquid chromatography for identification of mycobacterial species rarely encountered in clinical laboratories.

Authors:  E Tortoli; A Bartoloni; C Burrini; A Mantella; M T Simonetti
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-03       Impact factor: 3.267

8.  Heterogeneity and clonality among isolates of Mycobacterium kansasii: implications for epidemiological and pathogenicity studies.

Authors:  F Alcaide; I Richter; C Bernasconi; B Springer; C Hagenau; R Schulze-Röbbecke; E Tortoli; R Martín; E C Böttger; A Telenti
Journal:  J Clin Microbiol       Date:  1997-08       Impact factor: 5.948

9.  Identification of Mycobacterium kansasii by using a DNA probe (AccuProbe) and molecular techniques.

Authors:  E Richter; S Niemann; S Rüsch-Gerdes; S Hoffner
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

10.  False-positive Gen-Probe direct Mycobacterium tuberculosis amplification test results for patients with pulmonary M. kansasii and M. avium infections.

Authors:  J H Jorgensen; J R Salinas; R Paxson; K Magnon; J E Patterson; T F Patterson
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.